“Choi’l Pharmaceuticals’ New Drug Jacubo More Effective than PPI Treatment for Gastroesophageal Reflux Disease”

Article published in international medical journal in the field of gastroenterology covering phase 3 clinical trial content,
,
,

JW Pharmaceutical affiliate OncoTherapeutics’ advertisement image for Jacubojung developed by Jacubojung (Jeil Yak PPN) [Photo by Na Hwak-jin],
,
, “(Seoul=Yonhap News) By Na Hwak-jin = Jeil Pharmaceutical announced on the 21st that OncoTherapeutics, its affiliate, had developed a new drug for gastroesophageal reflux disease called ‘Jacubojung’ (active ingredient Jastaprazan), belonging to the P-CAB (Potassium-competitive acid blocker) class, which showed superior therapeutic effects compared to PPI (Proton Pump Inhibitor) class drugs traditionally used as standard treatments.”,
,
, “According to Jeil Pharmaceutical, the ‘American Journal of Gastroenterology’, a prestigious international academic journal in the field of gastroenterology, recently published a paper on the phase 3 clinical trial results of Jacubojung.”,
,
, ‘The phase 3 clinical trial of Jacubojung targeting 300 patients with mild reflux esophagitis was conducted at Seoul Asan Medical Center led by Professor Jeong Hoon-yong of the Department of Gastroenterology. Patients were divided into a group receiving Jastaprazan 20mg and a control group receiving the PPI drug Esomeprazole 40mg for up to 8 weeks.’,
,
, ‘As a result, after 8 weeks of treatment, the Jastaprazan group showed a superior efficacy with a cure rate of 97.9% compared to the control group’s 94.9%, and particularly, at 4 weeks of treatment, Jastaprazan showed a cure rate of 95.1%, which was 7.44 percentage points higher than the control group’s 87.7%, confirming its rapid efficacy, the paper reported.’,
,
, ‘In the analysis of side effects, no statistically significant differences were observed between the Jastaprazan group and the control group.’,
,
, ‘Kim Jon, CEO of OncoTherapeutics, said, “I am pleased that the phase 3 trial paper has been published in a prestigious gastroenterology journal, sharing the clinical results of this K-New Drug with the global medical community.” He added, “We will do our best for rapid commercialization in Korea and abroad, and will focus on expanding indications.”‘,
,
, ‘[email protected]’,
,
,